Apabetalone downregulates factors and pathways associated with vascular calcification

Gilham, D; Tsujikawa, LM; Sarsons, CD; Halliday, C; Wasiak, S; Stotz, SC; Jahagirdar, R; Sweeney, M; Johansson, JO; Wong, NCW; Kalantar-Zadeh, K; Kulikowski, E

Kulikowski, E (reprint author), Resverlogix Corp, 300-4820 Richard Rd SW, Calgary, AB T3E 6L1, Canada.

ATHEROSCLEROSIS, 2019; 280 (): 75

Abstract

Background and aims: Apabetalone is an inhibitor of bromodomain and extraterminal (BET) proteins. In clinical trials, apabetalone reduced the incidenc......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索